{
 "cells": [
  {
   "cell_type": "markdown",
   "metadata": {
    "id": "X4cRE8IbIrIV"
   },
   "source": [
    "<div style=\"font-variant: small-caps; \n",
    "      font-weight: normal; \n",
    "      font-size: 35px; \n",
    "      text-align: center; \n",
    "      padding: 15px; \n",
    "      margin: 10px;\">\n",
    "      Tokenization\n",
    "  </div> \n",
    "  \n",
    "<div style=\"\n",
    "      font-weight: normal; \n",
    "      font-size: 25px; \n",
    "      text-align: center; \n",
    "      padding: 15px; \n",
    "      margin: 10px;\">\n",
    "      Unigram tokenizer - Clinical Trials CTTI\n",
    "  </div> \n",
    "\n",
    "\n",
    "  <div style=\"\n",
    "      font-size: 15px; \n",
    "      line-height: 12px; \n",
    "      text-align: center; \n",
    "      padding: 15px; \n",
    "      margin: 10px;\">\n",
    "  Jean-baptiste AUJOGUE - Hybrid Intelligence\n",
    "  </div> \n",
    "\n",
    "  \n",
    "  <div style=\" float:right; \n",
    "      font-size: 12px; \n",
    "      line-height: 12px; \n",
    "  padding: 10px 15px 8px;\">\n",
    "  December 2022\n",
    "  </div>"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "<a id=\"TOC\"></a>"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "#### Table Of Content\n",
    "\n",
    "1. [Dataset](#data) <br>\n",
    "2. [ALBERT finetuning](#albert) <br>\n",
    "3. [Inference](#inference) <br>\n",
    "\n",
    "\n",
    "\n",
    "#### Reference\n",
    "\n",
    "- Hugginface full list of [tutorial notebooks](https://github.com/huggingface/transformers/tree/main/notebooks) (see also [here](https://huggingface.co/docs/transformers/main/notebooks#pytorch-examples))\n",
    "- Huggingface full list of [training scripts](https://github.com/huggingface/transformers/tree/main/examples/pytorch)\n",
    "- Huggingface [tutorial notebook](https://github.com/huggingface/notebooks/blob/main/examples/language_modeling_from_scratch.ipynb) on language models\n",
    "- Huggingface [course](https://huggingface.co/course/chapter7/3?fw=tf) on language models\n",
    "- Huggingface [training script](https://github.com/huggingface/transformers/blob/main/examples/pytorch/language-modeling/run_mlm.py) on language models\n",
    "- SentencePiece Unigram logic described in [Subword Regularization: Improving Neural Network Translation Models with Multiple Subword Candidates (2018)](https://arxiv.org/pdf/1804.10959.pdf)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [],
   "source": [
    "%load_ext autoreload\n",
    "%autoreload 2"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "C:\\Users\\jb\\miniconda3\\envs\\transformers_nlp\\lib\\site-packages\\tqdm\\auto.py:22: TqdmWarning: IProgress not found. Please update jupyter and ipywidgets. See https://ipywidgets.readthedocs.io/en/stable/user_install.html\n",
      "  from .autonotebook import tqdm as notebook_tqdm\n"
     ]
    }
   ],
   "source": [
    "import os\n",
    "import sys\n",
    "import re\n",
    "import random\n",
    "import copy\n",
    "import string\n",
    "import json\n",
    "from itertools import chain\n",
    "\n",
    "# data\n",
    "import pandas as pd\n",
    "import numpy as np\n",
    "from datasets import (\n",
    "    Dataset, \n",
    "    DatasetDict,\n",
    "    ClassLabel, \n",
    "    Features, \n",
    "    Sequence, \n",
    "    Value,\n",
    "    load_from_disk,\n",
    ")\n",
    "import transformers\n",
    "from transformers import AlbertConfig, AutoConfig, AutoTokenizer, AlbertTokenizerFast\n",
    "\n",
    "# tokenize\n",
    "from tokenizers import decoders, models, normalizers, pre_tokenizers, processors, trainers, Tokenizer"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "#### Transformers settings"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'4.22.2'"
      ]
     },
     "execution_count": 3,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "transformers.__version__"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "#### Custom paths & imports"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [],
   "source": [
    "path_to_repo = os.path.dirname(os.getcwd())\n",
    "path_to_data = os.path.join(path_to_repo, 'datasets')\n",
    "path_to_save = os.path.join(path_to_repo, 'saves', 'MLM')\n",
    "path_to_src  = os.path.join(path_to_repo, 'src')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [],
   "source": [
    "sys.path.insert(0, path_to_src)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "#### Constants"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [],
   "source": [
    "dataset_name = 'clinical trials CTTI/clinical-trials-ctti'\n",
    "base_model_name = \"albert-base-v2\"\n",
    "final_model_name = \"albert-small-ctti\""
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "<a id=\"data\"></a>"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "id": "whPRbBNbIrIl"
   },
   "source": [
    "# 1. Dataset\n",
    "\n",
    "[Table of content](#TOC)\n",
    "\n",
    "We generate a collection of instances of the `datasets.Dataset` class. \n",
    "\n",
    "Note that these are different from the fairly generic `torch.utils.data.Dataset` class. "
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## 1.1 Load Clinical Trials corpus\n",
    "\n",
    "[Table of content](#TOC)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {
    "scrolled": true
   },
   "outputs": [],
   "source": [
    "with open(os.path.join(path_to_data, '{}.txt'.format(dataset_name)), 'r', encoding = 'utf-8') as f:\n",
    "    texts = [t.strip() for t in f.readlines()]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {},
   "outputs": [],
   "source": [
    "dataset = Dataset.from_dict({'text': texts}, features = Features({'text': Value(dtype = 'string')}))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'text': ['This study will test the ability of extended release nifedipine (Procardia XL), a blood pressure medication, to permit a decrease in the dose of glucocorticoid medication children take to treat congenital adrenal hyperplasia (CAH). This protocol is designed to assess both acute and chronic effects of the calcium channel antagonist, nifedipine, on the hypothalamic-pituitary-adrenal axis in patients with congenital adrenal hyperplasia. The multicenter trial is composed of two phases and will involve a double-blind, placebo-controlled parallel design. The goal of Phase I is to examine the ability of nifedipine vs. placebo to decrease adrenocorticotropic hormone (ACTH) levels, as well as to begin to assess the dose-dependency of nifedipine effects. The goal of Phase II is to evaluate the long-term effects of nifedipine; that is, can attenuation of ACTH release by nifedipine permit a decrease in the dosage of glucocorticoid needed to suppress the HPA axis? Such a decrease would, in turn, reduce the deleterious effects of glucocorticoid treatment in CAH. diagnosed with Congenital Adrenal Hyperplasia (CAH), normal ECG during baseline evaluation, history of liver disease, or elevated liver function tests, history of cardiovascular disease',\n",
       "  'Inner city children are at an increased risk for lead overburden. This in turn affects cognitive functioning. However, the underlying neuropsychological effects of lead overburden and its age-specific effects have not been well delineated. This study is part of a larger study on the effects of lead overburden on the development of attention and memory. The larger study is using a multi-model approach to study the effects of lead overburden on these effects including the event-related potential (ERP), electrophysiologic measures of attention and memory are studied. Every eight months, for a total of three sessions the subjects will complete ERP measures of attention and memory which require them to watch various computer images while wearing scalp electrodes recording from 11 sites. It is this test that we are going to be doing on CRC. There will be 30 lead overburdened children recruited from the larger study for participation in the ERP studies on CRC. These 30 children will be matched with 30 children without lead overburden. This portion of the study is important in providing an index of physiological functioning to be used along with behaviorally based measures of attention and memory, and for providing information about the different measures.',\n",
       "  'The purpose of this study is to learn how the immune system works in response to vaccines. We will give the vaccines to subjects who have cancer but have not had treatment, and to patients who have had chemotherapy or stem cell transplant. Some patients will get vaccines while they are on treatments which boost the immune system (like the immune stimulating drug interleukin-2 or IL-2). Although we have safely treated many patients with immune boosting drugs, we do not yet know if they improve the body\\'s immune system to respond better to a vaccine. Some healthy volunteers will also be given the vaccines in order to serve as control subjects to get a good measure of the normal immune response. We will compare the patients and the healthy volunteers to study how their immune systems respond to the vaccines. There are several different types of white cells in the blood. We are interested in immune cells in the blood called T-cells. These T-cells detect foreign substances in the body (like viruses and cancer cells). We are trying to learn more about how the body fights these foreign substances. Our goal is to develop cancer vaccines which would teach T-cells to detect and kill cancer cells better. We know that in healthy people the immune system effectively protects against recurrent virus infection. For example, that is why people only get \"mono\" (mononucleosis) once under normal circumstances. When the body is infected with the \"mono\" virus, the immune system remembers and prevents further infection. We are trying to use the immune system to prevent cancer relapse. To test this, we will give two vaccines which have been used to measure these immune responses. Blood samples will be studied from cancer patients and will be compared to similar samples from normal subjects. Patients will receive each vaccine once only consisting of: Arm A: Intracel KLH 1000 mcg (1 mg) without adjuvant, subcutaneous Tetanus Toxoid 0.5 ml intramuscularly (this arm closed 1/2/02). Arm B: Biosyn KLH 1000 mcg (1 mg) without adjuvant, subcutaneous tetanus toxoid 0.5 ml intramuscularly (this arm closed 3/18/03). Arm C: Biosyn KLH 1000 mcg (1 mg) with Montanide ISA51 (now replaced with vegetable (VG) source after 8/31/06 to increase product safety) subcutaneous Tetanus toxoid 0.5 ml intramuscularly (this arm open 3/18/03). Subjects ineligible for tetanus may still receive KLH on this protocol. This is especially true given the national shortage of tetanus vaccines. Subjects will be eligible for tetanus when it becomes available if there has been no significant change in treatment interventions or overall health status and it is within 3 months of the KLH vaccine. Patients must have a diagnosis of cancer of any histologic type. Patients must have a Karnofsky performance status great or equal to 70%. Patients must have an expected survival for at least four months. Normal healthy volunteers to serve as control for this study. The occurrence of any type of neurologic symptoms to tetanus vaccine in th past. Patients with a history of seafood allergy are excluded from receiving KLH.']}"
      ]
     },
     "execution_count": 9,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "dataset[:3]"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "id": "YVx71GdAIrJH"
   },
   "source": [
    "## 1.2 Build tokenizer\n",
    "\n",
    "[Table of content](#TOC)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {},
   "outputs": [],
   "source": [
    "def batch_iterator(dataset, batch_size = 512):\n",
    "    for i in range(0, len(dataset), batch_size):\n",
    "        yield dataset[i: i + batch_size]['text']"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "metadata": {},
   "outputs": [],
   "source": [
    "base_tokenizer = AutoTokenizer.from_pretrained(base_model_name)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['<pad>', '<unk>', '[CLS]', '[SEP]', '[MASK]']"
      ]
     },
     "execution_count": 12,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "v2i = base_tokenizer.get_vocab()\n",
    "i2v = {i: v for v, i in v2i.items()}\n",
    "[i2v[i] for i in range(5)]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "metadata": {},
   "outputs": [],
   "source": [
    "# issue with this ! yields badly formed vocabulary, with punctuations at middle of tokens\n",
    "# tokenizer = base_tokenizer.train_new_from_iterator(batch_iterator(dataset, batch_size = 512), vocab_size = 5000)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "metadata": {},
   "outputs": [],
   "source": [
    "# see the different pre-tokenizers at https://huggingface.co/docs/tokenizers/components#pretokenizers\n",
    "# see also https://colab.research.google.com/github/huggingface/notebooks/blob/master/examples/tokenizer_training.ipynb#scrollTo=RZvnUm2PZV0H\n",
    "\n",
    "custom_pre_tokenizer = pre_tokenizers.Sequence([\n",
    "    # base albert pre-tokenizer\n",
    "    pre_tokenizers.WhitespaceSplit(),\n",
    "    pre_tokenizers.Metaspace(replacement = \"▁\", add_prefix_space = True),\n",
    "    \n",
    "    # isolate special characters in order not to have them at the middle of a word\n",
    "    # this is put after Metaspace in order not to include extra spaces\n",
    "    pre_tokenizers.Digits(),\n",
    "    pre_tokenizers.Punctuation(behavior = \"isolated\"),\n",
    "])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "metadata": {},
   "outputs": [],
   "source": [
    "tokenizer = Tokenizer(models.Unigram())\n",
    "tokenizer.normalizer     = base_tokenizer.backend_tokenizer.normalizer\n",
    "tokenizer.pre_tokenizer  = custom_pre_tokenizer #base_tokenizer.backend_tokenizer.pre_tokenizer \n",
    "tokenizer.post_processor = base_tokenizer.backend_tokenizer.post_processor\n",
    "tokenizer.decoder        = base_tokenizer.backend_tokenizer.decoder"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "metadata": {},
   "outputs": [],
   "source": [
    "# vocab_size has really unexpected behavior,\n",
    "# see https://github.com/huggingface/tokenizers/issues/903\n",
    "trainer = trainers.UnigramTrainer(\n",
    "    vocab_size = 10000, \n",
    "    special_tokens = ['<pad>', '<unk>', '[CLS]', '[SEP]', '[MASK]'], # order should be the same as base_tokenizer !\n",
    "    unk_token = \"<unk>\",\n",
    ")\n",
    "tokenizer.train_from_iterator(batch_iterator(dataset, batch_size = 512), trainer = trainer)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "metadata": {},
   "outputs": [],
   "source": [
    "tokenizer = AlbertTokenizerFast(tokenizer_object = tokenizer)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "('C:\\\\Users\\\\jb\\\\Desktop\\\\NLP\\\\perso - Transformers for NLP\\\\saves\\\\MLM\\\\albert-small-ctti\\\\tokenizer\\\\tokenizer_config.json',\n",
       " 'C:\\\\Users\\\\jb\\\\Desktop\\\\NLP\\\\perso - Transformers for NLP\\\\saves\\\\MLM\\\\albert-small-ctti\\\\tokenizer\\\\special_tokens_map.json',\n",
       " 'C:\\\\Users\\\\jb\\\\Desktop\\\\NLP\\\\perso - Transformers for NLP\\\\saves\\\\MLM\\\\albert-small-ctti\\\\tokenizer\\\\tokenizer.json')"
      ]
     },
     "execution_count": 18,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "tokenizer.save_pretrained(os.path.join(path_to_save, final_model_name, 'tokenizer'))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['<pad>', '<unk>', '[CLS]', '[SEP]', '[MASK]']"
      ]
     },
     "execution_count": 19,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "v2i = tokenizer.get_vocab()\n",
    "i2v = {i: v for v, i in v2i.items()}\n",
    "[i2v[i] for i in range(5)]"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "id": "YVx71GdAIrJH"
   },
   "source": [
    "## 1.3 Inspect tokenizer\n",
    "\n",
    "[Table of content](#TOC)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 20,
   "metadata": {},
   "outputs": [],
   "source": [
    "tokenizer = AutoTokenizer.from_pretrained(os.path.join(path_to_save, final_model_name, 'tokenizer'))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 21,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "10000"
      ]
     },
     "execution_count": 21,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(tokenizer.get_vocab())"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 22,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "<AxesSubplot: ylabel='Frequency'>"
      ]
     },
     "execution_count": 22,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 640x480 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "pd.DataFrame([len(t) for t in tokenizer.get_vocab()], columns = ['Length']).plot.hist(bins = 20)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 23,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['®',\n",
       " 'g',\n",
       " '!',\n",
       " 'σ',\n",
       " 'ε',\n",
       " '\\\\',\n",
       " '↓',\n",
       " 'π',\n",
       " 'p',\n",
       " '$',\n",
       " '≥',\n",
       " '●',\n",
       " 'κ',\n",
       " '±',\n",
       " 'т',\n",
       " '□',\n",
       " 'c',\n",
       " '、',\n",
       " '3',\n",
       " 'і',\n",
       " 'с',\n",
       " 'ω',\n",
       " '÷',\n",
       " '˃',\n",
       " '。',\n",
       " 'n',\n",
       " '↑',\n",
       " ')',\n",
       " 'ι',\n",
       " 'j',\n",
       " 'a',\n",
       " 'β',\n",
       " 'e',\n",
       " '~',\n",
       " '∙',\n",
       " '¬',\n",
       " '9',\n",
       " ']',\n",
       " 'r',\n",
       " '*',\n",
       " '·',\n",
       " 't',\n",
       " 'i',\n",
       " '¿',\n",
       " '}',\n",
       " 'δ',\n",
       " 'y',\n",
       " '>',\n",
       " 'τ',\n",
       " '{',\n",
       " 'q',\n",
       " '8',\n",
       " 'η',\n",
       " '▁',\n",
       " 'h',\n",
       " '(',\n",
       " '?',\n",
       " '§',\n",
       " '⁄',\n",
       " '˂',\n",
       " 'α',\n",
       " 'λ',\n",
       " 'ζ',\n",
       " '〗',\n",
       " 'd',\n",
       " '#',\n",
       " 'o',\n",
       " '%',\n",
       " 'ـ',\n",
       " '[',\n",
       " '|',\n",
       " '£',\n",
       " 'х',\n",
       " '\"',\n",
       " '\\u202c',\n",
       " '\\uf061',\n",
       " 'm',\n",
       " 'θ',\n",
       " '<',\n",
       " ';',\n",
       " 'l',\n",
       " '°',\n",
       " '€',\n",
       " '1',\n",
       " '•',\n",
       " 'χ',\n",
       " 'u',\n",
       " \"'\",\n",
       " '→',\n",
       " 'œ',\n",
       " '4',\n",
       " 'ı',\n",
       " '☐',\n",
       " 's',\n",
       " '7',\n",
       " '.',\n",
       " '∼',\n",
       " '×',\n",
       " 'w',\n",
       " '√',\n",
       " '∆',\n",
       " 'k',\n",
       " 'æ',\n",
       " '0',\n",
       " '≤',\n",
       " 'ß',\n",
       " 'ø',\n",
       " '†',\n",
       " '6',\n",
       " '⩾',\n",
       " 'v',\n",
       " '+',\n",
       " 'γ',\n",
       " 'μ',\n",
       " '=',\n",
       " '/',\n",
       " 'z',\n",
       " '△',\n",
       " '≈',\n",
       " '@',\n",
       " '≦',\n",
       " '-',\n",
       " ':',\n",
       " 'f',\n",
       " ',',\n",
       " '▪',\n",
       " 'ρ',\n",
       " '_',\n",
       " '‰',\n",
       " '5',\n",
       " '〖',\n",
       " '&',\n",
       " '≧',\n",
       " '◦',\n",
       " '^',\n",
       " '∞',\n",
       " '2',\n",
       " 'b',\n",
       " 'x',\n",
       " '©']"
      ]
     },
     "execution_count": 23,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "[t for t in tokenizer.get_vocab() if len(t) <= 1]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 24,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'cyclophosphamide': 2029,\n",
       " 'of': 725,\n",
       " '▁duration': 394,\n",
       " '▁pudendal': 9609,\n",
       " '▁day': 143,\n",
       " '▁preliminar': 1040,\n",
       " 'egenerative': 6804,\n",
       " '▁quantify': 2679,\n",
       " 'radiochemotherap': 9882,\n",
       " '▁polypropylen': 9455,\n",
       " 'muscarinic': 8862,\n",
       " '▁postprandial': 4013,\n",
       " '▁blockade': 3159,\n",
       " '▁parathyroid': 5544,\n",
       " '®': 475,\n",
       " '▁address': 1119,\n",
       " '▁areas': 1215,\n",
       " 'occlusive': 6070,\n",
       " '▁continuum': 8336,\n",
       " '▁aspects': 2110,\n",
       " '▁post': 165,\n",
       " '▁reoperation': 7724,\n",
       " '▁retinitis': 8404,\n",
       " 'elic': 7021,\n",
       " '▁pervasive': 8926,\n",
       " 'lawrence': 8928,\n",
       " 'approval': 9190,\n",
       " '▁anastomose': 9548,\n",
       " '▁concordance': 7164,\n",
       " '▁anatomy': 4059,\n",
       " 'mcl': 3208,\n",
       " '▁popularit': 8206,\n",
       " '▁variable': 1795,\n",
       " '▁participate': 344,\n",
       " '▁expensive': 4501,\n",
       " 'statistical': 8903,\n",
       " 'periosteal': 9408,\n",
       " '▁method': 467,\n",
       " '▁healthcare': 1052,\n",
       " '▁hearing': 1675,\n",
       " '▁worse': 2761,\n",
       " '▁levonorgestre': 9137,\n",
       " '▁passive': 3322,\n",
       " '▁speed': 2301,\n",
       " 'phos': 6838,\n",
       " '▁blank': 7835,\n",
       " '▁valvula': 4734,\n",
       " '▁colchicine': 7340,\n",
       " '▁sant': 7244,\n",
       " '▁trunk': 4020,\n",
       " 'lead': 4361,\n",
       " '▁adjudication': 9573,\n",
       " '▁practic': 6186,\n",
       " 'tocopherol': 9646,\n",
       " '▁pneumothorax': 6033,\n",
       " '▁lactose': 6063,\n",
       " '▁diminish': 7217,\n",
       " '▁bioinformatic': 9341,\n",
       " '▁excipients': 4855,\n",
       " '▁substantial': 2016,\n",
       " 'cost': 4823,\n",
       " 'pramipexol': 9572,\n",
       " 'take': 5578,\n",
       " '▁sensitivity': 868,\n",
       " '▁gauche': 9328,\n",
       " '▁marylan': 9424,\n",
       " '▁beginning': 1268,\n",
       " '95': 1337,\n",
       " 'quantitative': 7604,\n",
       " 'g': 53,\n",
       " 'iv': 617,\n",
       " 'masked': 4992,\n",
       " '▁analytical': 6394,\n",
       " '▁characteriz': 8171,\n",
       " '▁seem': 2240,\n",
       " '▁induc': 4123,\n",
       " '▁mouth': 1784,\n",
       " '▁membrane': 1846,\n",
       " 'assessment': 5288,\n",
       " '▁legal': 1959,\n",
       " '▁france': 2788,\n",
       " '▁paraffin': 7394,\n",
       " '!': 7543,\n",
       " '▁proxim': 7624,\n",
       " 'biopsie': 7966,\n",
       " 'communicable': 8504,\n",
       " '▁informal': 6983,\n",
       " '▁finland': 8081,\n",
       " '▁organ': 839,\n",
       " '▁plan': 740,\n",
       " '▁neurofibromatos': 9723,\n",
       " '▁regorafenib': 7971,\n",
       " '▁defined': 454,\n",
       " '▁respective': 2215,\n",
       " '▁magnetic': 1152,\n",
       " '▁selection': 1879,\n",
       " 'slice': 6793,\n",
       " '▁highly': 1339,\n",
       " '▁menstruation': 7658,\n",
       " '▁spastic': 7029,\n",
       " 'angiogenic': 5264,\n",
       " 'cvd': 4913,\n",
       " '▁moist': 7595,\n",
       " '▁focus': 952,\n",
       " '▁fidelit': 4806,\n",
       " '▁least': 190,\n",
       " 'necrosis': 3074,\n",
       " '▁tetraplegi': 9509,\n",
       " 'adsorption': 9649,\n",
       " '▁religious': 9397,\n",
       " '▁proteinuria': 4829,\n",
       " '▁spine': 1844,\n",
       " '▁endocrine': 2748,\n",
       " 'melanoma': 6309,\n",
       " 'phon': 6471,\n",
       " '▁cdc': 6746,\n",
       " '▁lipodystroph': 9525,\n",
       " '▁admitted': 1316,\n",
       " '▁glyc': 5475,\n",
       " '▁visuo': 8799,\n",
       " '▁proven': 1566,\n",
       " '▁groove': 9808,\n",
       " '▁apgar': 8152,\n",
       " '▁nor': 2812,\n",
       " '▁promise': 4954,\n",
       " '▁harm': 3055,\n",
       " '▁subacute': 6786,\n",
       " 'und': 3546,\n",
       " '▁college': 2796,\n",
       " '▁fasting': 1274,\n",
       " '▁peginterferon': 7864,\n",
       " '▁intra': 716,\n",
       " '▁palonos': 9725,\n",
       " '▁broad': 2431,\n",
       " '▁allergies': 2694,\n",
       " 'enhanced': 4545,\n",
       " '▁makes': 3389,\n",
       " '▁esophagus': 4025,\n",
       " '▁meningococc': 7842,\n",
       " '▁meconium': 9644,\n",
       " '▁range': 656,\n",
       " '▁inpatient': 1878,\n",
       " '▁propose': 1132,\n",
       " '▁aspirin': 2151,\n",
       " '▁permission': 5060,\n",
       " 'hyper': 5684,\n",
       " '▁pollutant': 9469,\n",
       " '▁somatic': 4618,\n",
       " '▁immunophenotyp': 9109,\n",
       " 'cellulose': 9246,\n",
       " '▁split': 4372,\n",
       " '▁iv': 354,\n",
       " '▁pathway': 1461,\n",
       " 'scopic': 5502,\n",
       " '▁liposomal': 5645,\n",
       " 'microenvironment': 6382,\n",
       " '▁appreciate': 9370,\n",
       " '▁approximatel': 510,\n",
       " '▁varie': 3448,\n",
       " '▁disoproxi': 9272,\n",
       " 'feasibilit': 9722,\n",
       " '▁lean': 4386,\n",
       " '▁employees': 5745,\n",
       " '▁mentione': 3979,\n",
       " 'when': 6840,\n",
       " '▁homocysteine': 7890,\n",
       " '▁drink': 2211,\n",
       " '▁exogenous': 6222,\n",
       " 'corona': 7117,\n",
       " 'σ': 9967,\n",
       " '▁adhd': 2534,\n",
       " '▁grocer': 9305,\n",
       " 'itsel': 3404,\n",
       " '▁vignette': 9788,\n",
       " '▁nevirapine': 8695,\n",
       " '▁course': 534,\n",
       " '▁timepoint': 6149,\n",
       " 'time': 1079,\n",
       " 'avi': 2897,\n",
       " '▁vulnerabl': 3247,\n",
       " '▁endoscopist': 5873,\n",
       " '▁intrahepatic': 7472,\n",
       " 'partial': 8208,\n",
       " 'reci': 5309,\n",
       " '▁phenylephrin': 7963,\n",
       " '▁mapping': 3980,\n",
       " '▁grasp': 7843,\n",
       " '▁low': 269,\n",
       " 'rated': 4065,\n",
       " 'neutral': 4728,\n",
       " 'psychiatry': 6207,\n",
       " '▁cardioverter': 7672,\n",
       " '▁circuit': 3787,\n",
       " '▁precursor': 5407,\n",
       " '▁volatile': 7676,\n",
       " '▁tomography': 1430,\n",
       " 'lizumab': 2888,\n",
       " '▁radioactive': 5657,\n",
       " 'steroid': 8491,\n",
       " '▁incarceration': 8780,\n",
       " '▁staining': 5262,\n",
       " '▁emphasize': 5412,\n",
       " '▁timeframe': 8777,\n",
       " '▁nifedip': 9167,\n",
       " '▁familiar': 4986,\n",
       " '▁reimbursement': 8229,\n",
       " '▁conscious': 6130,\n",
       " 'diabetic': 3857,\n",
       " 'pneumo': 6188,\n",
       " '▁reverse': 2799,\n",
       " '▁melphalan': 5558,\n",
       " '▁ensur': 5834,\n",
       " '▁favor': 4895,\n",
       " '500': 947,\n",
       " 'lactoferrin': 9288,\n",
       " 'glomerulonephrit': 9658,\n",
       " '▁locke': 6029,\n",
       " '▁massage': 4231,\n",
       " 'through': 6205,\n",
       " '▁researcher': 2678,\n",
       " 'ε': 9928,\n",
       " '▁term': 796,\n",
       " '▁future': 867,\n",
       " '▁mann': 4562,\n",
       " '▁anonymous': 6179,\n",
       " '▁neighbor': 9686,\n",
       " '▁park': 6988,\n",
       " '▁survivorship': 7179,\n",
       " 'tran': 5577,\n",
       " '▁recanalization': 8987,\n",
       " 'derived': 1387,\n",
       " '▁genes': 1684,\n",
       " '▁pulse': 1358,\n",
       " 'appropriate': 8194,\n",
       " '▁hypothetical': 9213,\n",
       " '▁locomotor': 8367,\n",
       " '▁assure': 6613,\n",
       " '▁esomeprazol': 8960,\n",
       " '▁activities': 891,\n",
       " 'less': 1230,\n",
       " '300': 1372,\n",
       " '▁vaginal': 1421,\n",
       " '▁claustrophobi': 9793,\n",
       " '▁expenditure': 3838,\n",
       " '▁enteral': 3862,\n",
       " '▁portugues': 9291,\n",
       " '▁identify': 447,\n",
       " '▁therapeutic': 567,\n",
       " '▁plaque': 1766,\n",
       " '▁oxygenation': 3001,\n",
       " '▁emphasis': 5820,\n",
       " '\\\\': 9014,\n",
       " 'riven': 5117,\n",
       " '▁indomethacin': 9114,\n",
       " '▁thermo': 4946,\n",
       " '▁gathere': 5389,\n",
       " '▁signs': 873,\n",
       " '▁possibilit': 2332,\n",
       " '▁hypothermi': 4771,\n",
       " '▁dried': 7078,\n",
       " '▁curettage': 9261,\n",
       " '▁telephonic': 9599,\n",
       " '▁transfer': 1764,\n",
       " '▁presente': 1936,\n",
       " '▁electromagnetic': 8011,\n",
       " '▁settings': 1558,\n",
       " 'continuation': 4698,\n",
       " 'aortic': 7556,\n",
       " '▁further': 363,\n",
       " '▁arrest': 2718,\n",
       " '▁sentinel': 4888,\n",
       " '▁dissolve': 8099,\n",
       " '▁subtle': 8143,\n",
       " 'intraventricular': 8343,\n",
       " '▁rep': 4297,\n",
       " '▁attachment': 4321,\n",
       " '▁femori': 9172,\n",
       " '▁skill': 3776,\n",
       " '▁multimodal': 3797,\n",
       " '▁format': 3998,\n",
       " '▁autistic': 8473,\n",
       " '▁joints': 4015,\n",
       " '▁variables': 726,\n",
       " '▁variance': 4169,\n",
       " '▁herbal': 5435,\n",
       " '▁meropenem': 9273,\n",
       " '▁inflammation': 712,\n",
       " '▁pilocarpin': 9938,\n",
       " 'peritoniti': 7065,\n",
       " '▁sch': 4675,\n",
       " '▁esophagogastr': 8377,\n",
       " 'meniscu': 8803,\n",
       " '▁exceeding': 6096,\n",
       " '▁costs': 1318,\n",
       " '▁reconstruct': 5453,\n",
       " 'voluntary': 7170,\n",
       " '▁scan': 862,\n",
       " 'fitzpatric': 8589,\n",
       " 'small': 2106,\n",
       " 'round': 5034,\n",
       " '▁homolog': 7332,\n",
       " '▁waitlist': 5791,\n",
       " '▁immunosuppresse': 9093,\n",
       " '▁unexpected': 5844,\n",
       " '▁valproic': 8601,\n",
       " '▁bmi': 970,\n",
       " '▁medicinal': 6165,\n",
       " 'genetic': 5832,\n",
       " 'dapt': 4876,\n",
       " 'fast': 4961,\n",
       " 'esthesia': 7123,\n",
       " 'dynamic': 6381,\n",
       " 'consent': 8114,\n",
       " '▁forearm': 4263,\n",
       " '▁comorbidity': 3789,\n",
       " '▁blinding': 4841,\n",
       " '▁catheterization': 3481,\n",
       " '▁acid': 573,\n",
       " '▁bile': 3641,\n",
       " 'obstruct': 6752,\n",
       " '▁problems': 747,\n",
       " '▁blend': 7632,\n",
       " 'from': 3982,\n",
       " '▁other': 99,\n",
       " '▁rare': 1912,\n",
       " '▁site': 602,\n",
       " '▁brain': 301,\n",
       " '▁decubit': 8748,\n",
       " '▁popular': 5035,\n",
       " '▁bicalutamid': 9427,\n",
       " 'molecular': 7993,\n",
       " '▁united': 1437,\n",
       " 'rolimus': 8280,\n",
       " '▁faster': 4103,\n",
       " '▁behavioral': 934,\n",
       " '▁infuse': 4128,\n",
       " '▁egg': 3827,\n",
       " '▁purposive': 9142,\n",
       " 'gestational': 8537,\n",
       " 'good': 7486,\n",
       " 'quality': 4911,\n",
       " 'expose': 7026,\n",
       " '▁mucosal': 3158,\n",
       " '▁intraocular': 3036,\n",
       " '▁resection': 948,\n",
       " 'graduate': 5263,\n",
       " '▁terminolog': 7302,\n",
       " '▁wor': 4060,\n",
       " '▁allocation': 1990,\n",
       " '▁survive': 5366,\n",
       " 'sens': 3072,\n",
       " '▁remove': 3137,\n",
       " '▁korean': 6155,\n",
       " '▁isoniazid': 8415,\n",
       " '08': 4405,\n",
       " 'provider': 8806,\n",
       " '▁delineate': 7342,\n",
       " '▁geometr': 8975,\n",
       " 'ever': 1341,\n",
       " '▁clinics': 1813,\n",
       " '▁symptomatolog': 5978,\n",
       " '▁spss': 3767,\n",
       " '▁activate': 4467,\n",
       " 'open': 4981,\n",
       " '▁specimen': 1632,\n",
       " '▁pc': 1343,\n",
       " '▁tutor': 8721,\n",
       " '▁occult': 7215,\n",
       " 'microcirculation': 6358,\n",
       " '▁not': 63,\n",
       " '▁adjudicate': 9661,\n",
       " 'morbiditie': 3934,\n",
       " '▁swab': 3890,\n",
       " '▁issue': 1955,\n",
       " 'opti': 4108,\n",
       " '▁restriction': 2322,\n",
       " 'placebo': 3298,\n",
       " '▁measuring': 1683,\n",
       " '▁uveiti': 5513,\n",
       " '▁thrombocytopeni': 9104,\n",
       " '▁qualification': 8880,\n",
       " '▁propensit': 7080,\n",
       " '▁oncologist': 5443,\n",
       " '▁reversal': 5788,\n",
       " 'thymocyte': 8395,\n",
       " '▁absorptiometry': 7079,\n",
       " '▁might': 1066,\n",
       " '▁moderate': 600,\n",
       " 'anger': 4850,\n",
       " '▁stethoscope': 9782,\n",
       " 'limab': 6134,\n",
       " '▁come': 2274,\n",
       " '▁complication': 1665,\n",
       " '▁linear': 2747,\n",
       " '▁meat': 6384,\n",
       " '▁palpation': 6906,\n",
       " '▁octreotid': 8478,\n",
       " '↓': 9978,\n",
       " '▁irrit': 4156,\n",
       " 'citabin': 9033,\n",
       " '▁proteomic': 6030,\n",
       " 'embolic': 7096,\n",
       " '▁cocain': 3962,\n",
       " '▁empiric': 8567,\n",
       " 'infarction': 9697,\n",
       " 'itting': 6577,\n",
       " '12': 133,\n",
       " 'bell': 6677,\n",
       " 'chron': 7230,\n",
       " '▁del': 3368,\n",
       " '▁synovial': 6917,\n",
       " '▁ruxolitin': 7684,\n",
       " '▁aggregation': 6389,\n",
       " 'female': 5320,\n",
       " '76': 3963,\n",
       " '▁misoprostol': 5316,\n",
       " '▁cystic': 3241,\n",
       " '▁otiti': 8089,\n",
       " '▁stockholm': 9191,\n",
       " '▁data': 91,\n",
       " '▁hyperinflation': 9008,\n",
       " '▁mania': 6969,\n",
       " '▁non': 118,\n",
       " '▁cortex': 2665,\n",
       " '▁bon': 5463,\n",
       " '▁prosthes': 7047,\n",
       " '▁subclavia': 9352,\n",
       " '▁circumference': 2898,\n",
       " 'tailor': 7906,\n",
       " '▁observation': 1385,\n",
       " '▁solution': 1270,\n",
       " '▁gel': 2224,\n",
       " '▁emotion': 4154,\n",
       " '▁dvt': 5930,\n",
       " '▁germ': 6606,\n",
       " '▁hemiparesi': 9006,\n",
       " '▁osteo': 3016,\n",
       " '▁inferior': 3611,\n",
       " 'mab': 3211,\n",
       " '▁brachytherapy': 5454,\n",
       " '▁easie': 5650,\n",
       " '▁somatostatin': 7818,\n",
       " 'stra': 3681,\n",
       " '▁societ': 8241,\n",
       " 'lut': 1963,\n",
       " '▁finnish': 9243,\n",
       " '▁help': 472,\n",
       " 'tolerant': 8915,\n",
       " '▁calcitonin': 9221,\n",
       " '▁antagonism': 9605,\n",
       " '▁depressive': 1624,\n",
       " 'π': 9972,\n",
       " '▁hyperglycemia': 4587,\n",
       " '▁focal': 3756,\n",
       " '▁adjunct': 4141,\n",
       " '▁sets': 4429,\n",
       " 'receptor': 4871,\n",
       " '▁permanent': 2298,\n",
       " '▁incubate': 9042,\n",
       " '▁hyperprolactin': 9862,\n",
       " 'responders': 2914,\n",
       " '▁youth': 1873,\n",
       " '▁regular': 832,\n",
       " 'shot': 5397,\n",
       " '▁los': 5920,\n",
       " 'cyte': 6034,\n",
       " '▁fish': 3540,\n",
       " '▁covered': 3843,\n",
       " '▁molecule': 2482,\n",
       " '▁normative': 7654,\n",
       " '▁forms': 1600,\n",
       " '▁seek': 1520,\n",
       " '▁calcification': 4977,\n",
       " '▁equation': 5295,\n",
       " '▁spouse': 7539,\n",
       " '▁eradicat': 8003,\n",
       " '▁macrophage': 4437,\n",
       " 'p': 39,\n",
       " '▁dilation': 4517,\n",
       " 'thalassemia': 6396,\n",
       " '▁bid': 3007,\n",
       " '▁condom': 5200,\n",
       " '▁zinc': 3973,\n",
       " '▁ffr': 5849,\n",
       " 'trip': 5841,\n",
       " '▁genetical': 6873,\n",
       " '▁original': 2326,\n",
       " '▁viabl': 6974,\n",
       " 'arotene': 8492,\n",
       " '▁living': 1087,\n",
       " 'nucleotide': 5215,\n",
       " 'ulation': 2971,\n",
       " '▁orally': 1616,\n",
       " '▁standard': 160,\n",
       " '▁epigenetic': 5794,\n",
       " '▁about': 243,\n",
       " '▁malignanc': 2177,\n",
       " 'aldes': 8273,\n",
       " '▁monotherapy': 2203,\n",
       " 'sixth': 7499,\n",
       " 'fibrosis': 1441,\n",
       " '▁asymptomatic': 2515,\n",
       " '▁escalation': 1812,\n",
       " '▁parasite': 4753,\n",
       " '▁concentrations': 1422,\n",
       " '▁modified': 1321,\n",
       " '▁ferritin': 5756,\n",
       " '▁hypoglycemia': 3444,\n",
       " 'chemoradiotherap': 4319,\n",
       " '▁diagnosis': 209,\n",
       " '▁qualify': 5012,\n",
       " '▁biodegrad': 9558,\n",
       " '▁convenience': 5428,\n",
       " '▁an': 55,\n",
       " 'hgb': 5981,\n",
       " 'generate': 4500,\n",
       " 'mmer': 5703,\n",
       " 'rtms': 6837,\n",
       " '▁ectopic': 7852,\n",
       " '▁is': 25,\n",
       " 'entering': 5348,\n",
       " '▁sars': 1621,\n",
       " '▁stagger': 9019,\n",
       " '▁assumed': 4892,\n",
       " '▁walnut': 9387,\n",
       " '▁increased': 367,\n",
       " '▁idiopathic': 2866,\n",
       " 'mutated': 6118,\n",
       " 'not': 2095,\n",
       " '▁pericarditis': 8756,\n",
       " '▁militar': 4588,\n",
       " '▁historical': 3291,\n",
       " 'dose': 797,\n",
       " '▁ingredients': 4668,\n",
       " '▁clinician': 2196,\n",
       " 'within': 2877,\n",
       " '▁fusion': 2911,\n",
       " '▁reg': 5744,\n",
       " '▁carolina': 7584,\n",
       " '▁phenotype': 2380,\n",
       " 'balance': 5651,\n",
       " '▁hour': 1078,\n",
       " '▁common': 322,\n",
       " 'king': 2832,\n",
       " '▁correlative': 6435,\n",
       " '49': 2732,\n",
       " 'wave': 4092,\n",
       " '▁bioavailabl': 9838,\n",
       " '▁heparin': 2564,\n",
       " 'eastern': 8321,\n",
       " '▁recall': 3761,\n",
       " '▁italian': 6078,\n",
       " '▁transit': 6467,\n",
       " 'relax': 5395,\n",
       " '▁nebulization': 9556,\n",
       " 'fluor': 6612,\n",
       " '▁utilization': 2271,\n",
       " 'tum': 2562,\n",
       " 'jejunal': 9396,\n",
       " '▁biopsychosocial': 9457,\n",
       " 'anti': 2467,\n",
       " '▁grade': 707,\n",
       " '▁gamma': 4524,\n",
       " '▁utiliz': 3239,\n",
       " '▁cigarette': 1927,\n",
       " 'gaul': 7274,\n",
       " '180': 2221,\n",
       " '▁tranexami': 6003,\n",
       " 'alcohol': 6818,\n",
       " '▁lactobacillus': 6183,\n",
       " 'rat': 3431,\n",
       " 'probnp': 6889,\n",
       " '▁try': 2477,\n",
       " '▁astrocytoma': 8970,\n",
       " '▁complexit': 7006,\n",
       " '▁calm': 6592,\n",
       " '▁inconclusive': 7980,\n",
       " '▁action': 1208,\n",
       " '▁carotenoid': 8949,\n",
       " '▁progress': 1864,\n",
       " '▁impairment': 724,\n",
       " 'hosphodiesterase': 8899,\n",
       " '▁accident': 3912,\n",
       " '▁visualization': 4209,\n",
       " '▁dairy': 6290,\n",
       " '▁bar': 2364,\n",
       " 'plasma': 6430,\n",
       " 'care': 1417,\n",
       " '▁origin': 2406,\n",
       " 'rick': 6653,\n",
       " 'herpetic': 8898,\n",
       " '▁tachyarrhythmia': 9269,\n",
       " '▁lac': 6202,\n",
       " 'dominance': 9148,\n",
       " '▁chi': 1848,\n",
       " '73': 2408,\n",
       " '▁fragment': 4384,\n",
       " 'screening': 4762,\n",
       " '▁reduce': 374,\n",
       " '42': 1986,\n",
       " '▁lasting': 3454,\n",
       " '$': 3944,\n",
       " 'gvhd': 4934,\n",
       " 'male': 5133,\n",
       " '▁random': 1586,\n",
       " 'flow': 3752,\n",
       " '▁intravascular': 5324,\n",
       " '▁diverse': 3961,\n",
       " '▁adenosine': 5680,\n",
       " '▁chimerism': 8586,\n",
       " 'chop': 5392,\n",
       " '▁cardio': 1738,\n",
       " '▁taxane': 5713,\n",
       " '▁factor': 664,\n",
       " '▁ablation': 1438,\n",
       " 'directed': 4359,\n",
       " '▁witness': 8010,\n",
       " 'per': 1166,\n",
       " '▁database': 1435,\n",
       " '▁histori': 6845,\n",
       " '▁amyloidosis': 6332,\n",
       " 'pressure': 7610,\n",
       " '▁chiropractic': 8791,\n",
       " '▁argentin': 9552,\n",
       " '▁endophthalmit': 9746,\n",
       " 'hypo': 5911,\n",
       " 'leukotriene': 8692,\n",
       " '▁subdivide': 9575,\n",
       " '≥': 192,\n",
       " '▁stop': 1036,\n",
       " '▁mrd': 5939,\n",
       " '▁letter': 3285,\n",
       " '▁media': 2291,\n",
       " '▁literac': 4445,\n",
       " '▁rem': 4239,\n",
       " '▁emerge': 7587,\n",
       " '▁recognize': 4783,\n",
       " 'rct': 2415,\n",
       " '▁optical': 3142,\n",
       " 'infrared': 4378,\n",
       " '▁schizo': 6649,\n",
       " '▁femoropoplitea': 9699,\n",
       " '▁dyad': 4649,\n",
       " '▁coping': 3124,\n",
       " '90': 489,\n",
       " '▁papilloma': 9406,\n",
       " 'bpm': 4106,\n",
       " '▁asses': 6996,\n",
       " '▁methodologie': 8256,\n",
       " 'convulsiv': 9667,\n",
       " '▁psychopatholog': 6588,\n",
       " '▁accordan': 2646,\n",
       " '▁observer': 5118,\n",
       " '▁epidemiologic': 6961,\n",
       " '▁coincide': 8522,\n",
       " 'location': 8671,\n",
       " 'ondylar': 9309,\n",
       " 'setting': 8382,\n",
       " '▁medial': 3735,\n",
       " 'ability': 233,\n",
       " 'in': 92,\n",
       " 'current': 5244,\n",
       " 'second': 5800,\n",
       " 'vic': 3729,\n",
       " '▁myeloid': 3120,\n",
       " 'thickness': 7889,\n",
       " '▁connected': 3483,\n",
       " '▁wa': 2957,\n",
       " 'prosthetic': 8388,\n",
       " '▁ergometer': 7420,\n",
       " 'compartmental': 8967,\n",
       " 'ciliary': 7653,\n",
       " '▁fibrin': 3464,\n",
       " 'ment': 848,\n",
       " '▁tmz': 8051,\n",
       " 'oxidation': 4900,\n",
       " '▁empath': 7455,\n",
       " 'watch': 6737,\n",
       " '▁quadrivalent': 8794,\n",
       " '▁nystagm': 9735,\n",
       " '▁ask': 2308,\n",
       " '▁inhibit': 2435,\n",
       " '▁fit': 2241,\n",
       " 'months': 2802,\n",
       " 'nine': 5193,\n",
       " '▁cleared': 6849,\n",
       " '▁valgu': 8439,\n",
       " '▁lab': 1640,\n",
       " '▁neuroleptic': 8080,\n",
       " '▁sickle': 3794,\n",
       " '▁found': 609,\n",
       " '▁muscular': 3177,\n",
       " '▁choroid': 9504,\n",
       " '▁thyroid': 1648,\n",
       " '▁eye': 729,\n",
       " '▁extension': 1693,\n",
       " '▁arrive': 6095,\n",
       " 'johnson': 8329,\n",
       " '▁represent': 1794,\n",
       " 'evaluat': 8993,\n",
       " '▁exponential': 9501,\n",
       " 'ometric': 5601,\n",
       " '▁autosomal': 7425,\n",
       " '▁excitability': 5593,\n",
       " '▁ease': 4249,\n",
       " '▁irreversibl': 4987,\n",
       " '▁thorough': 4978,\n",
       " '▁weekly': 949,\n",
       " '▁excision': 3837,\n",
       " '▁student': 2760,\n",
       " '▁abscess': 4887,\n",
       " '▁virologic': 5931,\n",
       " 'absorbable': 6823,\n",
       " '▁glycosylate': 8132,\n",
       " 'communicat': 6356,\n",
       " 'vascular': 2766,\n",
       " '▁tunnel': 4835,\n",
       " '▁nitrofurantoin': 9958,\n",
       " '▁enteca': 8952,\n",
       " '▁context': 1606,\n",
       " 'protective': 4463,\n",
       " '▁nausea': 1979,\n",
       " '▁bias': 2669,\n",
       " 'absorb': 6528,\n",
       " '▁run': 2033,\n",
       " '▁qtc': 4348,\n",
       " '▁proposed': 734,\n",
       " 'inositol': 8471,\n",
       " 'vigilance': 8709,\n",
       " '▁incorporate': 3022,\n",
       " '▁biologic': 2861,\n",
       " 'ogenic': 2974,\n",
       " 'amlodipine': 7089,\n",
       " '▁republic': 8215,\n",
       " '▁randomised': 1164,\n",
       " '●': 9971,\n",
       " '54': 3353,\n",
       " '▁initial': 570,\n",
       " '▁assume': 5784,\n",
       " '▁deaf': 6972,\n",
       " '▁include': 287,\n",
       " '▁osteosarcoma': 8124,\n",
       " '▁argument': 9286,\n",
       " '▁according': 303,\n",
       " 'oniz': 6484,\n",
       " '▁calorie': 4018,\n",
       " '▁controvers': 7283,\n",
       " '▁encrypt': 8487,\n",
       " 'ear': 1403,\n",
       " 'protection': 7421,\n",
       " '92': 3709,\n",
       " '▁resultant': 8238,\n",
       " 'ity': 408,\n",
       " '▁reported': 515,\n",
       " '▁segment': 1981,\n",
       " '▁secure': 2846,\n",
       " '▁think': 3941,\n",
       " '▁unnecessar': 4733,\n",
       " 'probiotics': 5108,\n",
       " 'third': 5330,\n",
       " 'nted': 5553,\n",
       " '▁scarce': 5990,\n",
       " '29': 1576,\n",
       " 'montelu': 7736,\n",
       " '▁med': 3595,\n",
       " '▁diverticul': 6709,\n",
       " 'tolerance': 9132,\n",
       " 'related': 446,\n",
       " '▁lateral': 1820,\n",
       " 'entra': 7573,\n",
       " '▁budget': 8620,\n",
       " '▁cancers': 2338,\n",
       " '▁led': 2674,\n",
       " '▁coronary': 577,\n",
       " 'experimental': 4526,\n",
       " 'pap': 5359,\n",
       " '▁hygien': 2778,\n",
       " '▁candidate': 1487,\n",
       " '2021': 3598,\n",
       " '▁serial': 3478,\n",
       " '▁fundus': 6065,\n",
       " '▁bleed': 6828,\n",
       " '▁dipstick': 8863,\n",
       " '▁adhere': 4043,\n",
       " '▁curvature': 8364,\n",
       " 'categor': 9017,\n",
       " '▁endocrinolog': 6993,\n",
       " '▁cetuximab': 3804,\n",
       " 'κ': 9389,\n",
       " '▁complement': 4677,\n",
       " 'dmard': 6503,\n",
       " 'filtration': 6585,\n",
       " 'function': 5053,\n",
       " '▁numerous': 2987,\n",
       " '▁bcl': 7596,\n",
       " '▁vesicle': 8832,\n",
       " '▁gestation': 2209,\n",
       " '▁hematoma': 5569,\n",
       " '▁frail': 5895,\n",
       " '▁diarrhoea': 6939,\n",
       " '▁postoperative': 468,\n",
       " 'giving': 6907,\n",
       " '▁bad': 4623,\n",
       " 'voluntaril': 9922,\n",
       " 'class': 4311,\n",
       " '▁cure': 2480,\n",
       " '▁systematical': 4875,\n",
       " '▁encode': 7941,\n",
       " '▁diastolic': 2590,\n",
       " '▁kcal': 6605,\n",
       " '▁osteoporos': 2881,\n",
       " '▁persistenc': 4400,\n",
       " '▁immunit': 3130,\n",
       " 'ular': 2132,\n",
       " '▁mechanisms': 991,\n",
       " '▁crp': 3872,\n",
       " '▁whose': 1676,\n",
       " '▁indocyanine': 8075,\n",
       " 'hnscc': 7113,\n",
       " '▁dietician': 8350,\n",
       " '▁same': 387,\n",
       " 'sion': 1833,\n",
       " '▁mentor': 6167,\n",
       " '▁lecture': 8373,\n",
       " 'laboratory': 9247,\n",
       " '▁secondary': 280,\n",
       " 'surgery': 3250,\n",
       " '▁histolog': 3661,\n",
       " 'ologic': 5604,\n",
       " 'specified': 4898,\n",
       " 'after': 1539,\n",
       " '▁since': 606,\n",
       " '▁indian': 5732,\n",
       " '▁electro': 1806,\n",
       " 'titration': 9144,\n",
       " 'tinib': 4455,\n",
       " 'pri': 1780,\n",
       " '▁filgrastim': 6084,\n",
       " '▁questionnaire': 456,\n",
       " '▁soon': 3547,\n",
       " '▁hypotheses': 2048,\n",
       " '▁forward': 4257,\n",
       " '▁medication': 318,\n",
       " '▁previous': 251,\n",
       " 'cranial': 4130,\n",
       " '▁socioeconomic': 4686,\n",
       " '▁neovascular': 5070,\n",
       " '▁registration': 2182,\n",
       " '▁arterial': 1004,\n",
       " '▁ropivacaine': 5301,\n",
       " 'bleeding': 7168,\n",
       " 'losing': 8117,\n",
       " 'obturator': 8825,\n",
       " '▁vitreo': 8939,\n",
       " '▁combination': 294,\n",
       " '▁sports': 3594,\n",
       " '▁statement': 5304,\n",
       " 'report': 2289,\n",
       " '▁pure': 5073,\n",
       " '▁landscape': 9452,\n",
       " '▁thromboembolic': 4945,\n",
       " '▁classic': 5519,\n",
       " '▁open': 348,\n",
       " '▁metallic': 6126,\n",
       " 'via': 3364,\n",
       " '▁cabazitax': 9340,\n",
       " '▁respiratory': 502,\n",
       " '▁acquire': 1845,\n",
       " '▁alleviat': 7121,\n",
       " '▁pelvis': 4494,\n",
       " '▁neointima': 9368,\n",
       " '▁childbearin': 3037,\n",
       " '▁administrative': 5075,\n",
       " '▁otolaryngolog': 9419,\n",
       " '▁stimuli': 3063,\n",
       " '▁reasonable': 5403,\n",
       " '▁osimertinib': 8151,\n",
       " '▁inference': 9450,\n",
       " '▁computed': 2529,\n",
       " '▁alendron': 9316,\n",
       " '▁schwannoma': 9873,\n",
       " '▁cryotherap': 6608,\n",
       " '▁tracheostom': 6101,\n",
       " 'severe': 3451,\n",
       " '▁prednisolone': 6275,\n",
       " '▁lubricant': 9447,\n",
       " '▁cor': 3461,\n",
       " '▁brushing': 7022,\n",
       " '▁arbitra': 9610,\n",
       " '▁venous': 1207,\n",
       " '▁impairments': 3425,\n",
       " '▁mepolizumab': 9294,\n",
       " '▁parkinsonism': 8551,\n",
       " '▁gleno': 7220,\n",
       " '▁ambulance': 7884,\n",
       " '▁actigraph': 6224,\n",
       " '▁cadaver': 8539,\n",
       " '▁abutment': 7361,\n",
       " '▁fda': 1523,\n",
       " '▁summar': 3109,\n",
       " '▁profiles': 2471,\n",
       " '▁haemorrhage': 6293,\n",
       " 'potecan': 6322,\n",
       " '▁imperative': 7776,\n",
       " '▁monitoring': 557,\n",
       " 'ating': 1262,\n",
       " '▁spermicide': 8761,\n",
       " 'ly': 47,\n",
       " '▁coagulopath': 3259,\n",
       " '▁assign': 4849,\n",
       " 'rain': 5715,\n",
       " '±': 1671,\n",
       " '▁obsessive': 7235,\n",
       " '▁apical': 5739,\n",
       " '▁filter': 4035,\n",
       " '▁understudie': 9491,\n",
       " '▁gather': 3854,\n",
       " 'abl': 3144,\n",
       " '▁empirical': 4272,\n",
       " '▁papillomavirus': 7515,\n",
       " 'lectromyographic': 9364,\n",
       " '▁conform': 5659,\n",
       " 'т': 9991,\n",
       " '▁infiltrate': 6654,\n",
       " '▁infected': 1798,\n",
       " '▁constitute': 3966,\n",
       " '▁ards': 4011,\n",
       " '▁psychotherap': 3422,\n",
       " '▁varice': 4923,\n",
       " '▁analyse': 2074,\n",
       " 'epoetin': 6491,\n",
       " '▁transferrin': 7428,\n",
       " '▁entrance': 8901,\n",
       " 'definition': 9731,\n",
       " '▁febuxost': 9894,\n",
       " '▁illnesses': 3597,\n",
       " '▁lung': 361,\n",
       " 'fertile': 6667,\n",
       " '▁pancreatiti': 3215,\n",
       " 'challenge': 9122,\n",
       " '▁ignore': 9226,\n",
       " '▁obinutuz': 8868,\n",
       " '▁tobacco': 1829,\n",
       " '▁nut': 6243,\n",
       " '▁allopurin': 8641,\n",
       " '▁lymphadenopath': 9362,\n",
       " '▁intention': 2225,\n",
       " 'thrombotic': 4664,\n",
       " 'two': 4357,\n",
       " '▁outreach': 6538,\n",
       " '▁holter': 6564,\n",
       " '▁damage': 1015,\n",
       " 'closed': 6791,\n",
       " '▁distract': 8732,\n",
       " '▁latter': 4423,\n",
       " 'decrease': 9077,\n",
       " '▁motivat': 9126,\n",
       " '▁granulomato': 8860,\n",
       " '▁obscure': 9463,\n",
       " 'due': 5584,\n",
       " 'cip': 3621,\n",
       " '▁duchenne': 9507,\n",
       " '▁resumption': 9197,\n",
       " '▁web': 2118,\n",
       " '▁humidifie': 9076,\n",
       " 'education': 6168,\n",
       " '▁absorbe': 5522,\n",
       " '▁generalized': 3744,\n",
       " '▁bradycardia': 5620,\n",
       " 'triol': 8431,\n",
       " '▁honey': 8507,\n",
       " 'embryonic': 8500,\n",
       " 'pped': 5400,\n",
       " 'peripheral': 9097,\n",
       " '▁blurr': 9531,\n",
       " 'occurring': 7837,\n",
       " '▁devise': 9062,\n",
       " '□': 9954,\n",
       " '▁endotracheal': 3592,\n",
       " 'book': 3984,\n",
       " '▁oral': 281,\n",
       " '▁pills': 4525,\n",
       " 'cardia': 7723,\n",
       " '▁no': 87,\n",
       " '▁granulocyte': 5445,\n",
       " '▁through': 256,\n",
       " 'like': 2041,\n",
       " 'ductal': 5903,\n",
       " '▁rates': 586,\n",
       " '▁urge': 6903,\n",
       " '▁contribute': 1241,\n",
       " '▁their': 86,\n",
       " '▁messenger': 8824,\n",
       " '▁caregiver': 2008,\n",
       " 'striatal': 8776,\n",
       " '▁opportunit': 5291,\n",
       " '▁decide': 3600,\n",
       " '▁mesylate': 5815,\n",
       " '▁hypothesis': 440,\n",
       " '▁vasoactive': 7204,\n",
       " ...}"
      ]
     },
     "execution_count": 24,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "tokenizer.get_vocab()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 25,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "('This study will test the ability of extended release nifedipine (Procardia XL), a blood pressure medication, to permit a decrease in the dose of glucocorticoid medication children take to treat congenital adrenal hyperplasia (CAH). This protocol is designed to assess both acute and chronic effects of the calcium channel antagonist, nifedipine, on the hypothalamic-pituitary-adrenal axis in patients with congenital adrenal hyperplasia. The multicenter trial is composed of two phases and will involve a double-blind, placebo-controlled parallel design. The goal of Phase I is to examine the ability of nifedipine vs. placebo to decrease adrenocorticotropic hormone (ACTH) levels, as well as to begin to assess the dose-dependency of nifedipine effects. The goal of Phase II is to evaluate the long-term effects of nifedipine; that is, can attenuation of ACTH release by nifedipine permit a decrease in the dosage of glucocorticoid needed to suppress the HPA axis? Such a decrease would, in turn, reduce the deleterious effects of glucocorticoid treatment in CAH. diagnosed with Congenital Adrenal Hyperplasia (CAH), normal ECG during baseline evaluation, history of liver disease, or elevated liver function tests, history of cardiovascular disease',\n",
       " '[CLS] this study will test the ability of extended release nifedipine (procardia xl), a blood pressure medication, to permit a decrease in the dose of glucocorticoid medication children take to treat congenital adrenal hyperplasia (cah). this protocol is designed to assess both acute and chronic effects of the calcium channel antagonist, nifedipine, on the hypothalamic-pituitary-adrenal axis in patients with congenital adrenal hyperplasia. the multicenter trial is composed of two phases and will involve a double-blind, placebo-controlled parallel design. the goal of phase i is to examine the ability of nifedipine vs. placebo to decrease adrenocorticotropic hormone (acth) levels, as well as to begin to assess the dose-dependency of nifedipine effects. the goal of phase ii is to evaluate the long-term effects of nifedipine; that is, can attenuation of acth release by nifedipine permit a decrease in the dosage of glucocorticoid needed to suppress the hpa axis? such a decrease would, in turn, reduce the deleterious effects of glucocorticoid treatment in cah. diagnosed with congenital adrenal hyperplasia (cah), normal ecg during baseline evaluation, history of liver disease, or elevated liver function tests, history of cardiovascular disease[SEP]')"
      ]
     },
     "execution_count": 25,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "texts[0], tokenizer.decode(tokenizer(texts[0])['input_ids'])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 26,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[('▁this', 38),\n",
       " ('▁study', 28),\n",
       " ('▁will', 22),\n",
       " ('▁test', 122),\n",
       " ('▁the', 7),\n",
       " ('▁', 5),\n",
       " ('ability', 233),\n",
       " ('▁of', 9),\n",
       " ('▁extended', 2023),\n",
       " ('▁release', 1289),\n",
       " ('▁nifedip', 9167),\n",
       " ('in', 92),\n",
       " ('e', 20),\n",
       " ('▁', 5),\n",
       " ('(', 19),\n",
       " ('pro', 922),\n",
       " ('cardia', 7723),\n",
       " ('▁', 5),\n",
       " ('x', 125),\n",
       " ('l', 35),\n",
       " (')', 18),\n",
       " (',', 6),\n",
       " ('▁', 5),\n",
       " ('a', 11),\n",
       " ('▁blood', 80),\n",
       " ('▁pressure', 245),\n",
       " ('▁medication', 318),\n",
       " (',', 6),\n",
       " ('▁to', 13),\n",
       " ('▁permit', 4364),\n",
       " ('▁', 5),\n",
       " ('a', 11),\n",
       " ('▁decrease', 580),\n",
       " ('▁in', 15),\n",
       " ('▁the', 7),\n",
       " ('▁dose', 106),\n",
       " ('▁of', 9),\n",
       " ('▁glucocorticoid', 6067),\n",
       " ('▁medication', 318),\n",
       " ('▁children', 172),\n",
       " ('▁take', 479),\n",
       " ('▁to', 13),\n",
       " ('▁treat', 844),\n",
       " ('▁congenital', 1636),\n",
       " ('▁adrenal', 4276),\n",
       " ('▁hyperplasia', 5496),\n",
       " ('▁', 5),\n",
       " ('(', 19),\n",
       " ('c', 31),\n",
       " ('a', 11),\n",
       " ('h', 57),\n",
       " (')', 18),\n",
       " ('.', 8),\n",
       " ('▁this', 38),\n",
       " ('▁protocol', 285),\n",
       " ('▁is', 25),\n",
       " ('▁', 5),\n",
       " ('designed', 470),\n",
       " ('▁to', 13),\n",
       " ('▁assess', 161),\n",
       " ('▁both', 182),\n",
       " ('▁acute', 223),\n",
       " ('▁and', 12),\n",
       " ('▁chronic', 174),\n",
       " ('▁effects', 144),\n",
       " ('▁of', 9),\n",
       " ('▁the', 7),\n",
       " ('▁calcium', 1486),\n",
       " ('▁channel', 3565),\n",
       " ('▁antagonist', 2371),\n",
       " (',', 6),\n",
       " ('▁nifedip', 9167),\n",
       " ('in', 92),\n",
       " ('e', 20),\n",
       " (',', 6),\n",
       " ('▁on', 41),\n",
       " ('▁the', 7),\n",
       " ('▁hypothalamic', 7988),\n",
       " ('-', 14),\n",
       " ('pituitary', 4757),\n",
       " ('-', 14),\n",
       " ('a', 11),\n",
       " ('d', 16),\n",
       " ('renal', 4427),\n",
       " ('▁axis', 3299),\n",
       " ('▁in', 15),\n",
       " ('▁patients', 29),\n",
       " ('▁with', 23),\n",
       " ('▁congenital', 1636),\n",
       " ('▁adrenal', 4276),\n",
       " ('▁hyperplasia', 5496),\n",
       " ('.', 8),\n",
       " ('▁the', 7),\n",
       " ('▁multicenter', 843),\n",
       " ('▁trial', 98),\n",
       " ('▁is', 25),\n",
       " ('▁compose', 3625),\n",
       " ('d', 16),\n",
       " ('▁of', 9),\n",
       " ('▁two', 108),\n",
       " ('▁phases', 3045),\n",
       " ('▁and', 12),\n",
       " ('▁will', 22),\n",
       " ('▁involve', 685),\n",
       " ('▁', 5),\n",
       " ('a', 11),\n",
       " ('▁double', 478),\n",
       " ('-', 14),\n",
       " ('blind', 658),\n",
       " (',', 6),\n",
       " ('▁placebo', 204),\n",
       " ('-', 14),\n",
       " ('controlled', 783),\n",
       " ('▁parallel', 1151),\n",
       " ('▁design', 330),\n",
       " ('.', 8),\n",
       " ('▁the', 7),\n",
       " ('▁goal', 640),\n",
       " ('▁of', 9),\n",
       " ('▁phase', 152),\n",
       " ('▁', 5),\n",
       " ('i', 21),\n",
       " ('▁is', 25),\n",
       " ('▁to', 13),\n",
       " ('▁examine', 546),\n",
       " ('▁the', 7),\n",
       " ('▁', 5),\n",
       " ('ability', 233),\n",
       " ('▁of', 9),\n",
       " ('▁nifedip', 9167),\n",
       " ('in', 92),\n",
       " ('e', 20),\n",
       " ('▁', 5),\n",
       " ('v', 66),\n",
       " ('s', 10),\n",
       " ('.', 8),\n",
       " ('▁placebo', 204),\n",
       " ('▁to', 13),\n",
       " ('▁decrease', 580),\n",
       " ('▁adreno', 8602),\n",
       " ('cortico', 4650),\n",
       " ('tropic', 4583),\n",
       " ('▁hormone', 889),\n",
       " ('▁', 5),\n",
       " ('(', 19),\n",
       " ('act', 1217),\n",
       " ('h', 57),\n",
       " (')', 18),\n",
       " ('▁levels', 240),\n",
       " (',', 6),\n",
       " ('▁as', 43),\n",
       " ('▁well', 179),\n",
       " ('▁as', 43),\n",
       " ('▁to', 13),\n",
       " ('▁begin', 1737),\n",
       " ('▁to', 13),\n",
       " ('▁assess', 161),\n",
       " ('▁the', 7),\n",
       " ('▁dose', 106),\n",
       " ('-', 14),\n",
       " ('dependenc', 5132),\n",
       " ('y', 30),\n",
       " ('▁of', 9),\n",
       " ('▁nifedip', 9167),\n",
       " ('in', 92),\n",
       " ('e', 20),\n",
       " ('▁effects', 144),\n",
       " ('.', 8),\n",
       " ('▁the', 7),\n",
       " ('▁goal', 640),\n",
       " ('▁of', 9),\n",
       " ('▁phase', 152),\n",
       " ('▁', 5),\n",
       " ('i', 21),\n",
       " ('i', 21),\n",
       " ('▁is', 25),\n",
       " ('▁to', 13),\n",
       " ('▁evaluate', 119),\n",
       " ('▁the', 7),\n",
       " ('▁long', 302),\n",
       " ('-', 14),\n",
       " ('term', 424),\n",
       " ('▁effects', 144),\n",
       " ('▁of', 9),\n",
       " ('▁nifedip', 9167),\n",
       " ('in', 92),\n",
       " ('e', 20),\n",
       " (';', 62),\n",
       " ('▁that', 50),\n",
       " ('▁is', 25),\n",
       " (',', 6),\n",
       " ('▁can', 101),\n",
       " ('▁attenuation', 7615),\n",
       " ('▁of', 9),\n",
       " ('▁act', 1394),\n",
       " ('h', 57),\n",
       " ('▁release', 1289),\n",
       " ('▁by', 48),\n",
       " ('▁nifedip', 9167),\n",
       " ('in', 92),\n",
       " ('e', 20),\n",
       " ('▁permit', 4364),\n",
       " ('▁', 5),\n",
       " ('a', 11),\n",
       " ('▁decrease', 580),\n",
       " ('▁in', 15),\n",
       " ('▁the', 7),\n",
       " ('▁dosage', 1704),\n",
       " ('▁of', 9),\n",
       " ('▁glucocorticoid', 6067),\n",
       " ('▁', 5),\n",
       " ('needed', 753),\n",
       " ('▁to', 13),\n",
       " ('▁', 5),\n",
       " ('s', 10),\n",
       " ('up', 163),\n",
       " ('p', 39),\n",
       " ('ress', 4495),\n",
       " ('▁the', 7),\n",
       " ('▁', 5),\n",
       " ('h', 57),\n",
       " ('p', 39),\n",
       " ('a', 11),\n",
       " ('▁axis', 3299),\n",
       " ('?', 1161),\n",
       " ('▁such', 183),\n",
       " ('▁', 5),\n",
       " ('a', 11),\n",
       " ('▁decrease', 580),\n",
       " ('▁would', 373),\n",
       " (',', 6),\n",
       " ('▁in', 15),\n",
       " ('▁turn', 2668),\n",
       " (',', 6),\n",
       " ('▁reduce', 374),\n",
       " ('▁the', 7),\n",
       " ('▁deleterious', 6307),\n",
       " ('▁effects', 144),\n",
       " ('▁of', 9),\n",
       " ('▁glucocorticoid', 6067),\n",
       " ('▁treatment', 51),\n",
       " ('▁in', 15),\n",
       " ('▁ca', 883),\n",
       " ('h', 57),\n",
       " ('.', 8),\n",
       " ('▁diagnosed', 481),\n",
       " ('▁with', 23),\n",
       " ('▁congenital', 1636),\n",
       " ('▁adrenal', 4276),\n",
       " ('▁hyperplasia', 5496),\n",
       " ('▁', 5),\n",
       " ('(', 19),\n",
       " ('c', 31),\n",
       " ('a', 11),\n",
       " ('h', 57),\n",
       " (')', 18),\n",
       " (',', 6),\n",
       " ('▁normal', 273),\n",
       " ('▁ecg', 1656),\n",
       " ('▁during', 81),\n",
       " ('▁baseline', 213),\n",
       " ('▁evaluation', 335),\n",
       " (',', 6),\n",
       " ('▁history', 128),\n",
       " ('▁of', 9),\n",
       " ('▁liver', 336),\n",
       " ('▁disease', 60),\n",
       " (',', 6),\n",
       " ('▁or', 27),\n",
       " ('▁elevated', 1588),\n",
       " ('▁liver', 336),\n",
       " ('▁function', 150),\n",
       " ('▁tests', 405),\n",
       " (',', 6),\n",
       " ('▁history', 128),\n",
       " ('▁of', 9),\n",
       " ('▁cardiovascular', 505),\n",
       " ('▁disease', 60)]"
      ]
     },
     "execution_count": 26,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "tokens = tokenizer.tokenize(texts[0])\n",
    "ids = tokenizer(texts[0])['input_ids'][1:-1]\n",
    "list(zip(tokens, ids))"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### TODO\n",
    "\n",
    "- show examples of randomness in tokenization"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "[Table of content](#TOC)"
   ]
  }
 ],
 "metadata": {
  "colab": {
   "name": "Token Classification",
   "provenance": []
  },
  "kernelspec": {
   "display_name": "Python 3 (ipykernel)",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.8.13"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 1
}
